drugset / Trial / NCT04391062
Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma
Phase 2
Completed
14 enrolled
University Hospital, Lille
Hemerion Therapeutics · collabInstitut National de la Santé Et de la Recherche Médicale, France · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The phase II study evaluate a light dose escalation in a classical intraoperative PDT regimen mediated by 5-ALA-PpIX, in glioblastoma patients with access to full surgical removal of the contrast enhancement. This treatment will be performed in addition to the current reference treatment of glioblastoma: maximum removal surgery followed by radiochemotherapy according to the Stupp protocol.
Timeline
- Start
- 2021-09-28
- Primary completion
- 2024-03-25
- Completion
- 2024-03-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Aminolevulinic Acid | Diagnostic / imaging agent | — | Oral |